Quest Products LLC Launches a Nasal Filter Device that Blocks Microscopic Airborne Particles and Pollutants

Quest Products, LLC introduces a new nasal filter designed for people interested in protection against the smallest of airborne particles and pollutants.

Its unique filtration material is electrostatically charged to better capture microscopic particles and protect people from droplets released during coughing and sneezing. In a study by LMS Technologies, the new breatheWELL Nasal Filter was proven as a unique barrier against airborne particles measuring as small as 3 microns. In fact, the study demonstrated a 90 percent effectiveness against particles measuring 10 microns and 60 percent effectiveness against particles measuring 2.5 microns—this is within the micron measurement range of the smallest sized bacteria, pollen and allergen. According to the results of the study, the nasal filters can block up to 99% of airborne particles and pollutants.

“In recent news reports, immunology and allergy specialists encourage people to do all they can to alleviate inflammation to the lungs caused by breathing in common allergens because it may leave them more susceptible to respiratory illnesses,” said Jon Romanow, Director of Marketing, Quest Products, LLC. “We believe that our new product will be helpful to people seeking additional options to protect their overall health by blocking the inhalation of pollens, pollutants and bacteria that reach the lungs through the nose. These filters are ideal for protection during travel when around pets or while working in dusty environments.”

The unique filtration material makes breatheWELL™ a reliable option for reducing direct and indirect airborne transmission of unwanted particles breatheWELL™ nasal filters fit discreetly into the front of the nostrils. It is drug-free, latex-free and the rings are made of a surgical-grade polymer that is non-toxic.

breatheWELL™ is available now for purchase online at Amazon and at breatheandsleepwell.com.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.